For diagnosis of chronic lymphocytic leukaemia, Multiplicom announce CLL MASTR Plus kit

  • Posted on: 7 July 2015
  • By: Shalini.Sharma

GPAT courses

Pharma courses

pharma courses

pharma courses



Multiplicom N.V., announced the launch of a new gene panel, the CLL MASTR Plus kit, to improve the diagnosis of patients with chronic lymphocytic leukaemia.

Chronic Lymphocytic Leukaemia Chronic lymphocytic leukaemia (CLL) is a type of slow growing leukaemia that affects developing B-lymphocytes . This is the most common form of leukaemia in adults and has a highly variable outcome. Genetic analysis is an important tool in the differential diagnosis and distinguishes between ‘stable disease’ and ‘progression’. The CLL MASTR Plus kit allows the detection of single nucleotide variants as well as copy number alterations. The identification of mutations in TP53, BIRC3, NOTCH1 and SF3B1 enables a more refined prognostic stratification, while the detection of TP53 mutations has therapeutic value as it guides treatment with alemtuzumab and/or steroids, which may be followed by allogeneic stem cell transplantation.

This new test enables personalised medicine for patients with CLL. Multiplicom’s test helps to steer the treatment options to stabilise the disease.


<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>



 

Latest News